AR025060A1 - Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa - Google Patents
Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosaInfo
- Publication number
- AR025060A1 AR025060A1 ARP000104064A ARP000104064A AR025060A1 AR 025060 A1 AR025060 A1 AR 025060A1 AR P000104064 A ARP000104064 A AR P000104064A AR P000104064 A ARP000104064 A AR P000104064A AR 025060 A1 AR025060 A1 AR 025060A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydroxypropilmetilcellulose
- capsules
- pharmaceutical formulations
- formulations
- solubilized
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una formulacion farmacéutica oral que comprende, en una cápsula de hidroxipropilmetilcelulosa, un análogo de camptotecina dispersado o solubilizado en unamatriz semi-solida. Estas formulaciones son utiles para el tratamiento de enfermedadesneoplásic as.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9918885.6A GB9918885D0 (en) | 1999-08-10 | 1999-08-10 | Pharmaceutical formulations in hydroxypropymethycellulose capsules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR025060A1 true AR025060A1 (es) | 2002-11-06 |
Family
ID=10858930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000104064A AR025060A1 (es) | 1999-08-10 | 2000-08-07 | Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6569452B1 (es) |
| EP (1) | EP1126851B1 (es) |
| CN (1) | CN1245976C (es) |
| AR (1) | AR025060A1 (es) |
| AT (1) | ATE262905T1 (es) |
| AU (1) | AU6158200A (es) |
| CA (1) | CA2354039C (es) |
| CO (1) | CO5200854A1 (es) |
| CZ (1) | CZ293749B6 (es) |
| DE (1) | DE60009442D1 (es) |
| EA (1) | EA200100568A1 (es) |
| GB (1) | GB9918885D0 (es) |
| HK (1) | HK1040930B (es) |
| HU (1) | HUP0104476A3 (es) |
| IL (2) | IL143502A0 (es) |
| NO (1) | NO319712B1 (es) |
| PE (1) | PE20010407A1 (es) |
| WO (1) | WO2001010443A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925127D0 (en) * | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
| DE60314378T2 (de) * | 2002-03-01 | 2008-02-28 | Pfizer Italia S.R.L. | Kristalline polymorphe form von irinotecanhydrochlorid |
| CN1316970C (zh) * | 2002-11-14 | 2007-05-23 | 武汉华中科大纳米药业有限公司 | 一种羟喜树碱固体分散物及其制剂 |
| JP2005183361A (ja) * | 2003-10-03 | 2005-07-07 | Ngk Insulators Ltd | 電子放出素子、電子放出装置、ディスプレイ及び光源 |
| US20050208146A1 (en) * | 2003-10-30 | 2005-09-22 | Pfizer Inc | Novel dosage and administration method for oral camptosar |
| GT200500310A (es) | 2004-11-19 | 2006-06-19 | Compuestos organicos | |
| SA06270147B1 (ar) | 2005-06-09 | 2009-12-22 | نوفارتيس ايه جي | عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين |
| WO2007033522A1 (fr) * | 2005-09-21 | 2007-03-29 | Shenzhen Tys R & D Co., Ltd. | Formulation de gélule contenant de la moxifloxacine et son procédé de préparation |
| GB0526419D0 (en) * | 2005-12-23 | 2006-02-08 | Cyclacel Ltd | Formulation |
| WO2008038944A1 (en) * | 2006-09-26 | 2008-04-03 | Samyang Corporation | Submicron nanoparticle of poorly water soluble camptothecin derivatives and process for preparation thereof |
| WO2012174731A1 (en) * | 2011-06-24 | 2012-12-27 | Cheng Haiyung | Method and improved pharmaceutical composition for improving the absorption of an ester prodrug |
| CN103110605A (zh) * | 2011-11-17 | 2013-05-22 | 天士力制药集团股份有限公司 | 一种热熔胶囊制剂及其制备方法 |
| CN110946836A (zh) * | 2014-01-17 | 2020-04-03 | 昂科拉制药有限公司 | 用于治疗癌症的伊立替康的固体口服剂型 |
| CN105287427B (zh) * | 2015-10-20 | 2017-04-19 | 沈阳红旗制药有限公司 | 一种利福平半固体胶囊及其制备方法 |
| KR102066402B1 (ko) * | 2017-12-22 | 2020-01-15 | 대화제약 주식회사 | 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4678516A (en) * | 1984-10-09 | 1987-07-07 | The Dow Chemical Company | Sustained release dosage form based on highly plasticized cellulose ether gels |
| DE69531611T2 (de) * | 1994-04-28 | 2004-02-26 | Bionumerik Pharmaceuticals, Inc., San Antonio | Lactone-stabile camptothecin oder 7 - ethyl camptothecin - formulierung in dimethylisosorbid oder dimethylacetamid |
| US5597829A (en) | 1994-05-09 | 1997-01-28 | Bionumerik Pharmaceuticals, Inc. | Lactone stable formulation of camptothecin and methods for uses thereof |
| US5756123A (en) * | 1994-12-01 | 1998-05-26 | Japan Elanco Co., Ltd. | Capsule shell |
| US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
| CN1088584C (zh) * | 1996-08-02 | 2002-08-07 | 久光制药株式会社 | 口服制剂用胶囊及口服胶囊制剂 |
| AR013261A1 (es) * | 1997-08-01 | 2000-12-13 | Smithkline Beecham Corp | Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina |
-
1999
- 1999-08-10 GB GBGB9918885.6A patent/GB9918885D0/en not_active Ceased
-
2000
- 2000-07-11 HU HU0104476A patent/HUP0104476A3/hu unknown
- 2000-07-11 EP EP00947971A patent/EP1126851B1/en not_active Expired - Lifetime
- 2000-07-11 HK HK02102740.7A patent/HK1040930B/zh not_active IP Right Cessation
- 2000-07-11 CN CNB008021422A patent/CN1245976C/zh not_active Expired - Fee Related
- 2000-07-11 CZ CZ20012089A patent/CZ293749B6/cs not_active IP Right Cessation
- 2000-07-11 AT AT00947971T patent/ATE262905T1/de not_active IP Right Cessation
- 2000-07-11 AU AU61582/00A patent/AU6158200A/en not_active Abandoned
- 2000-07-11 DE DE60009442T patent/DE60009442D1/de not_active Expired - Lifetime
- 2000-07-11 US US09/857,188 patent/US6569452B1/en not_active Expired - Fee Related
- 2000-07-11 CA CA002354039A patent/CA2354039C/en not_active Expired - Fee Related
- 2000-07-11 EA EA200100568A patent/EA200100568A1/ru unknown
- 2000-07-11 WO PCT/EP2000/006590 patent/WO2001010443A1/en not_active Ceased
- 2000-07-11 IL IL14350200A patent/IL143502A0/xx active IP Right Grant
- 2000-08-07 AR ARP000104064A patent/AR025060A1/es unknown
- 2000-08-07 PE PE2000000795A patent/PE20010407A1/es not_active Application Discontinuation
- 2000-08-08 CO CO00059172A patent/CO5200854A1/es not_active Application Discontinuation
-
2001
- 2001-05-31 IL IL143502A patent/IL143502A/en not_active IP Right Cessation
- 2001-06-26 NO NO20013205A patent/NO319712B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1126851B1 (en) | 2004-03-31 |
| CZ293749B6 (cs) | 2004-07-14 |
| US6569452B1 (en) | 2003-05-27 |
| WO2001010443A1 (en) | 2001-02-15 |
| CO5200854A1 (es) | 2002-09-27 |
| CN1327387A (zh) | 2001-12-19 |
| HUP0104476A2 (hu) | 2002-03-28 |
| CZ20012089A3 (cs) | 2001-10-17 |
| CA2354039C (en) | 2008-09-23 |
| GB9918885D0 (en) | 1999-10-13 |
| PE20010407A1 (es) | 2001-03-28 |
| HK1040930A1 (en) | 2002-06-28 |
| ATE262905T1 (de) | 2004-04-15 |
| NO20013205L (no) | 2001-06-26 |
| HUP0104476A3 (en) | 2004-05-28 |
| CN1245976C (zh) | 2006-03-22 |
| IL143502A (en) | 2006-12-10 |
| EP1126851A1 (en) | 2001-08-29 |
| IL143502A0 (en) | 2002-04-21 |
| NO20013205D0 (no) | 2001-06-26 |
| DE60009442D1 (de) | 2004-05-06 |
| HK1040930B (zh) | 2006-10-27 |
| NO319712B1 (no) | 2005-09-05 |
| AU6158200A (en) | 2001-03-05 |
| EA200100568A1 (ru) | 2001-10-22 |
| CA2354039A1 (en) | 2001-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR025060A1 (es) | Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa | |
| ECSP083351A (es) | Composiciones farmacéuticas | |
| AP1954A (en) | Controlled release compositions comprising nimesulide. | |
| EE03805B1 (et) | Peroraalselt manustatava farmatseutilise kompositsiooni kasutamine meeste erektiilse talitlushäire raviks ettenähtud ravimi valmistamiseks | |
| UY27455A1 (es) | Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos. | |
| AR026610A1 (es) | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central | |
| CO5170471A1 (es) | Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio | |
| ATE224717T1 (de) | Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin | |
| AR032293A1 (es) | Estuche farmaceutico | |
| PA8606201A1 (es) | DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN | |
| ATE292453T1 (de) | Antivirale arznei | |
| HRP20010684B1 (hr) | Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina | |
| ATE262893T1 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
| AR021086A1 (es) | Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento. | |
| AR028448A1 (es) | Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares | |
| UY25798A1 (es) | Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico. | |
| AR034142A1 (es) | Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion | |
| CO4970832A1 (es) | Nuevas formulaciones y procesos para su fabricacion | |
| ECSP003607A (es) | Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa | |
| DE60214476D1 (de) | Pharmazeutische Zubereitungen, Wirkstoffe enthaltend, die sich für unerlaubte Verabreichung anbieten | |
| MY141008A (en) | Oral formulations of deoxypeganine and their uses | |
| AR027677A1 (es) | Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer | |
| DK1499278T3 (da) | Farmaceutisk doseringsform, som udviser umiddelbar frigivelse, og som omfatter polymorf tibolon | |
| AR031846A1 (es) | Combinacion de sustancias activas, medicamentos y formulaciones que la contienen, y uso de la misma para la preparacion de un medicamento para el tratamiento del dolor | |
| BR9710629A (pt) | Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |